IN2013MN01188A - - Google Patents

Download PDF

Info

Publication number
IN2013MN01188A
IN2013MN01188A IN1188MUN2013A IN2013MN01188A IN 2013MN01188 A IN2013MN01188 A IN 2013MN01188A IN 1188MUN2013 A IN1188MUN2013 A IN 1188MUN2013A IN 2013MN01188 A IN2013MN01188 A IN 2013MN01188A
Authority
IN
India
Prior art keywords
lutetium
radiotherapy
tumor
novel
directed
Prior art date
Application number
Inventor
Sandra Borkowski
Rosalba Mansi
Helmut Mäcke
Original Assignee
Piramal Imaging Sa
Universitätsspital Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Imaging Sa, Universitätsspital Basel filed Critical Piramal Imaging Sa
Publication of IN2013MN01188A publication Critical patent/IN2013MN01188A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention is directed to novel Lutetium 177 labeled bombesin analogs for treatment of tumor by radiotherapy.
IN1188MUN2013 2010-11-22 2011-11-21 IN2013MN01188A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10075743 2010-11-22
PCT/EP2011/070553 WO2012069410A1 (en) 2010-11-22 2011-11-21 177lutetium-labeled bombesin analogs for radiotherapy

Publications (1)

Publication Number Publication Date
IN2013MN01188A true IN2013MN01188A (en) 2015-07-10

Family

ID=45001762

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1188MUN2013 IN2013MN01188A (en) 2010-11-22 2011-11-21

Country Status (15)

Country Link
US (1) US20140023585A1 (en)
EP (1) EP2643024A1 (en)
JP (1) JP2014500262A (en)
KR (1) KR20140053819A (en)
CN (1) CN103476434A (en)
AU (1) AU2011333948A1 (en)
BR (1) BR112013012503A2 (en)
CA (1) CA2818694A1 (en)
EA (1) EA026443B1 (en)
IL (1) IL226498A0 (en)
IN (1) IN2013MN01188A (en)
MX (1) MX2013005697A (en)
NZ (1) NZ610740A (en)
SG (1) SG190371A1 (en)
WO (1) WO2012069410A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100900A1 (en) * 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
CA2886068C (en) 2012-09-25 2021-06-22 Advanced Accelerator Applications Usa, Inc. Radiolabeled grpr-antagonists for diagnostic imaging and treatment of grpr-positive cancer
CN106039327A (en) * 2016-06-14 2016-10-26 宁波益格爱生物科技有限公司 GRPR targeted molecular probe and preparation method thereof
MA46864A (en) * 2016-11-17 2021-04-28 Minerva Imaging Aps FACTOR VII INHIBITED BY THE ACTIVE SITE MARKED BY 177-LU
CA3153267A1 (en) * 2019-12-19 2021-06-24 Hans-Jurgen Wester Modified grpr antagonist peptides for imaging and therapy of cancer
EP4282439A1 (en) * 2022-05-23 2023-11-29 Erasmus University Rotterdam Medical Center Radioisotope labeled sstr2-agonists with linkers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100900A1 (en) * 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates

Also Published As

Publication number Publication date
JP2014500262A (en) 2014-01-09
WO2012069410A1 (en) 2012-05-31
IL226498A0 (en) 2013-07-31
BR112013012503A2 (en) 2016-11-08
CA2818694A1 (en) 2012-05-31
EA026443B1 (en) 2017-04-28
KR20140053819A (en) 2014-05-08
EA201300611A1 (en) 2014-04-30
SG190371A1 (en) 2013-06-28
EP2643024A1 (en) 2013-10-02
AU2011333948A1 (en) 2013-06-06
NZ610740A (en) 2015-08-28
US20140023585A1 (en) 2014-01-23
MX2013005697A (en) 2014-08-01
CN103476434A (en) 2013-12-25

Similar Documents

Publication Publication Date Title
PH12017501817A1 (en) Heterocyclic compounds as lsd1 inhibitors
MX2020010496A (en) Inhibitors of lysine specific demethylase-1.
PH12015502839B1 (en) Antiviral compounds
SG190785A1 (en) Antiviral compounds
CR20130045A (en) THERAPEUTIC COMPOUNDS
PH12016500225A1 (en) Novel quinoline-substituted compound
MX2017006382A (en) Phospholipid ether analogs as cancer-targeting drug vehicles.
IN2014MN02459A (en)
EA201200999A1 (en) METHODS OF TREATMENT BREAST CANCER
IN2014CN04067A (en)
IN2013MN01188A (en)
TN2014000415A1 (en) Novel thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof
MX351863B (en) Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof.
MX2011011431A (en) Composition for the treatment of prostate cancer.
MX346095B (en) Novel imidazole amines as modulators of kinase activity.
MX2016008259A (en) Process methods for phosphatidylinositol 3-kinase inhibitors.
TN2012000610A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
BR112014014896A2 (en) new combination
ZA201300762B (en) Novel combination therapy for the treatment of cancer
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
MX2014001810A (en) Use of ccne2 as a stratification marker in the treatment of breast tumours with novel pan-cdk inhibitors.
MX347541B (en) Sialic acid analogs.
MX2013011694A (en) Taxane and abeo-taxane analogs.
MX2015005312A (en) 1 h-indole-3-carboxamide derivatives and use thereof as p2y12 antagonists.
MX2013006670A (en) 2-carboxamide-4-piperazinyl-benzofuran derivative.